APO-RIVASTIGMINE PATCH 15 rivastigmine 13.3 mg/24 hours transdermal drug delivery system sachet

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

rivastigmine, Quantity: 27 mg

Disponible depuis:

Arrotex Pharmaceuticals Pty Ltd

DCI (Dénomination commune internationale):

Rivastigmine

forme pharmaceutique:

Drug delivery system, transdermal

Composition:

Excipient Ingredients: acrylates copolymer; ethyl acetate; hexane; 2-ethylhexyl acrylate; methyl acrylate; acrylic acid; acrylates/ethylhexyl acrylate copolymer; methylated trimethylated silica

Mode d'administration:

Transdermal

Unités en paquet:

30 sachets, 7 sachets

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

APO-RIVASTIGMINE PATCH is indicated for the treatment of patients with mild, moderate and severe dementia of the Alzheimer?s type.

Descriptif du produit:

Visual Identification: Circular 15cm2 transdermal patch, tri-layer adhesive matrix, translucent white backing film labelled with "Rivastigmine 13.3 mg/24 h"; Container Type: Sachet; Container Material: Other composite material; Container Life Time: 2 Years; Container Temperature: Store below 25 degrees Celsius

Statut de autorisation:

Licence status A

Date de l'autorisation:

2017-01-25